Retour
Retour
Marc Le Bozec
Interim Chief Executive Officer
- Equipe de direction
- Marc currently supports numerous biotech companies as an advisor, board member, and investor.
- Between 2015 and 2023, he created and managed two biotech investment funds within Financière Arbevel. There, he completed 11 investments and 2 exits: TransCure bioServicessold to Cathay Capital (4x) in early 2022 and Imactis sold to GE Healthcare (2x) in early 2023.
- Previously, he was Chief Financial Officer of Cellectis, where he raised €120 million and prepared the Nasdaq listing. He also led and turned around CYTOO.
- A graduate of HEC in 1992, Marc began his career in organizational consulting (Bossard Consultants), then in strategy consulting (Arthur D. Little). He founded his first biotech company, BioProteinTechnologies, in 1998.